These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 20944124)
1. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. Yiu CC; Chanplakorn N; Chan MS; Loo WT; Chow LW; Toi M; Sasano H Anticancer Res; 2010 Sep; 30(9):3465-72. PubMed ID: 20944124 [TBL] [Abstract][Full Text] [Related]
2. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319 [TBL] [Abstract][Full Text] [Related]
3. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients. Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578 [TBL] [Abstract][Full Text] [Related]
4. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625 [TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors: cellular and molecular effects. Miller WR; Anderson TJ; White S; Larionov A; Murray J; Evans D; Krause A; Dixon JM J Steroid Biochem Mol Biol; 2005 May; 95(1-5):83-9. PubMed ID: 16002280 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689 [TBL] [Abstract][Full Text] [Related]
7. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Freedman OC; Verma S; Clemons MJ Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700 [TBL] [Abstract][Full Text] [Related]
8. Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance. Yiu CC; Sasano H; Ono K; Chow LW Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S79-89. PubMed ID: 20374034 [TBL] [Abstract][Full Text] [Related]
9. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846 [TBL] [Abstract][Full Text] [Related]
10. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane. Bertelsen BE; Almås B; Fjermeros K; Viste K; Geisler SB; Sauer T; Selsås K; Geisler J Breast Cancer Res Treat; 2024 Jul; 206(2):347-358. PubMed ID: 38649619 [TBL] [Abstract][Full Text] [Related]
11. Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Chan MS; Wang L; Chanplakorn N; Tamaki K; Ueno T; Toi M; Loo WT; Chow LW; Suzuki T; Sasano H Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S69-78. PubMed ID: 22309693 [TBL] [Abstract][Full Text] [Related]
12. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127 [TBL] [Abstract][Full Text] [Related]
13. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment. Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867 [TBL] [Abstract][Full Text] [Related]
15. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703 [TBL] [Abstract][Full Text] [Related]
16. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938 [TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors and breast cancer. Macedo LF; Sabnis G; Brodie A Ann N Y Acad Sci; 2009 Feb; 1155():162-73. PubMed ID: 19250202 [TBL] [Abstract][Full Text] [Related]
18. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550 [TBL] [Abstract][Full Text] [Related]
19. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449 [TBL] [Abstract][Full Text] [Related]
20. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Tubiana-Hulin M; Becette V; Bieche I; Mauriac L; Romieu G; Bibeau F; Macgrogan G; Bourgeois H; Chollet P; Defrance R; Spyratos F Anticancer Res; 2007; 27(4C):2689-96. PubMed ID: 17695434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]